Which has better valuation & earnings, ENGN or PRTA?

enGene has higher earnings, but lower revenue than Prothena. Prothena is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$2.17 N/A Prothena $9.68M 50.46 -$244.09M -$0.84 N/A

Is ENGN or PRTA more profitable?

enGene has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat enGene's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -56.06% -45.64% Prothena -80.68% -16.45% -14.51%

Does the media refer more to ENGN or PRTA?

In the previous week, enGene had 6 more articles in the media than Prothena. MarketBeat recorded 8 mentions for enGene and 2 mentions for Prothena. Prothena's average media sentiment score of 1.61 beat enGene's score of 0.48 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Prothena 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better earnings & valuation, EVMN or ENGN?

Evommune has higher revenue and earnings than enGene. Evommune is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evommune $13M 36.43 -$68.87M -$11.03 N/A enGene N/A N/A -$117.30M -$2.17 N/A

Is EVMN or ENGN more profitable?

enGene's return on equity of -56.06% beat Evommune's return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A -62.63% -40.55% enGene N/A -56.06% -45.64%

Does the media prefer EVMN or ENGN?

In the previous week, enGene had 6 more articles in the media than Evommune. MarketBeat recorded 8 mentions for enGene and 2 mentions for Evommune. Evommune's average media sentiment score of 0.89 beat enGene's score of 0.48 indicating that Evommune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive enGene 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, ENGN or CCCC?

C4 Therapeutics has higher revenue and earnings than enGene. C4 Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$2.17 N/A C4 Therapeutics $35.95M 13.18 -$104.99M -$1.00 N/A

Is ENGN or CCCC more profitable?

enGene has a net margin of 0.00% compared to C4 Therapeutics' net margin of -289.44%. C4 Therapeutics' return on equity of -45.45% beat enGene's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -56.06% -45.64% C4 Therapeutics -289.44% -45.45% -30.90%

Does the media prefer ENGN or CCCC?

In the previous week, enGene had 3 more articles in the media than C4 Therapeutics. MarketBeat recorded 8 mentions for enGene and 5 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.11 beat enGene's score of 0.48 indicating that C4 Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral C4 Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, AGMB or ENGN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A -$70.77M N/A N/A enGene N/A N/A -$117.30M -$2.17 N/A

Is AGMB or ENGN more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat enGene's return on equity. Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A enGene N/A -56.06% -45.64%

Does the media prefer AGMB or ENGN?

In the previous week, enGene had 4 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 8 mentions for enGene and 4 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.72 beat enGene's score of 0.48 indicating that AgomAb Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive enGene 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, ENGN or KMDA?

Kamada has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$2.17 N/A Kamada $180.46M 2.64 $20.20M $0.38 21.82

Is ENGN or KMDA more profitable?

Kamada has a net margin of 11.60% compared to enGene's net margin of 0.00%. Kamada's return on equity of 8.37% beat enGene's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -56.06% -45.64% Kamada 11.60% 8.37% 5.85%

enGene (ENGN) Competitors

$1.82 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$1.87 +0.05 (+2.52%)

As of 04:00 AM Eastern

Compare

ENGN vs. PRTA, EVMN, CCCC, AGMB, and KMDA

Should you buy enGene stock or one of its competitors? enGene's main competitors and comparable companies include Prothena (PRTA), Evommune (EVMN), C4 Therapeutics (CCCC), AgomAb Therapeutics (AGMB), and Kamada (KMDA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does enGene compare to Prothena?

enGene (NASDAQ:ENGN) and Prothena (NASDAQ:PRTA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

enGene has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
Prothena	-80.68%	-16.45%	-14.51%

In the previous week, enGene had 6 more articles in the media than Prothena. MarketBeat recorded 8 mentions for enGene and 2 mentions for Prothena. Prothena's average media sentiment score of 1.61 beat enGene's score of 0.48 indicating that Prothena is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prothena	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

64.2% of enGene shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 10.5% of enGene shares are owned by insiders. Comparatively, 10.4% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

enGene has higher earnings, but lower revenue than Prothena. Prothena is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.17	N/A
Prothena	$9.68M	50.46	-$244.09M	-$0.84	N/A

enGene presently has a consensus price target of $11.05, indicating a potential upside of 505.23%. Prothena has a consensus price target of $24.57, indicating a potential upside of 163.36%. Given enGene's higher probable upside, equities research analysts clearly believe enGene is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

enGene has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market. Comparatively, Prothena has a beta of -0.29, suggesting that its share price is 129% less volatile than the broader market.

Summary

Prothena beats enGene on 9 of the 16 factors compared between the two stocks.

How does enGene compare to Evommune?

Evommune (NYSE:EVMN) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

Evommune currently has a consensus price target of $41.56, suggesting a potential upside of 218.43%. enGene has a consensus price target of $11.05, suggesting a potential upside of 505.23%. Given enGene's higher probable upside, analysts plainly believe enGene is more favorable than Evommune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

enGene's return on equity of -56.06% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	-62.63%	-40.55%
enGene	N/A	-56.06%	-45.64%

In the previous week, enGene had 6 more articles in the media than Evommune. MarketBeat recorded 8 mentions for enGene and 2 mentions for Evommune. Evommune's average media sentiment score of 0.89 beat enGene's score of 0.48 indicating that Evommune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
enGene	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Evommune has higher revenue and earnings than enGene. Evommune is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	36.43	-$68.87M	-$11.03	N/A
enGene	N/A	N/A	-$117.30M	-$2.17	N/A

64.2% of enGene shares are held by institutional investors. 31.1% of Evommune shares are held by company insiders. Comparatively, 10.5% of enGene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Evommune beats enGene on 8 of the 14 factors compared between the two stocks.

How does enGene compare to C4 Therapeutics?

enGene (NASDAQ:ENGN) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

enGene has a beta of -0.28, indicating that its stock price is 128% less volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.91, indicating that its stock price is 191% more volatile than the broader market.

C4 Therapeutics has higher revenue and earnings than enGene. C4 Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.17	N/A
C4 Therapeutics	$35.95M	13.18	-$104.99M	-$1.00	N/A

enGene has a net margin of 0.00% compared to C4 Therapeutics' net margin of -289.44%. C4 Therapeutics' return on equity of -45.45% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
C4 Therapeutics	-289.44%	-45.45%	-30.90%

In the previous week, enGene had 3 more articles in the media than C4 Therapeutics. MarketBeat recorded 8 mentions for enGene and 5 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.11 beat enGene's score of 0.48 indicating that C4 Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
C4 Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

64.2% of enGene shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 10.5% of enGene shares are owned by company insiders. Comparatively, 5.6% of C4 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

enGene currently has a consensus target price of $11.05, suggesting a potential upside of 505.23%. C4 Therapeutics has a consensus target price of $7.75, suggesting a potential upside of 101.30%. Given enGene's higher probable upside, analysts clearly believe enGene is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
C4 Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

C4 Therapeutics beats enGene on 10 of the 15 factors compared between the two stocks.

How does enGene compare to AgomAb Therapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

AgomAb Therapeutics currently has a consensus price target of $37.50, indicating a potential upside of 184.74%. enGene has a consensus price target of $11.05, indicating a potential upside of 505.23%. Given enGene's higher probable upside, analysts plainly believe enGene is more favorable than AgomAb Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A
enGene	N/A	N/A	-$117.30M	-$2.17	N/A

In the previous week, enGene had 4 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 8 mentions for enGene and 4 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.72 beat enGene's score of 0.48 indicating that AgomAb Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
enGene	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

AgomAb Therapeutics' return on equity of 0.00% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
enGene	N/A	-56.06%	-45.64%

64.2% of enGene shares are owned by institutional investors. 10.5% of enGene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

AgomAb Therapeutics beats enGene on 6 of the 10 factors compared between the two stocks.

How does enGene compare to Kamada?

enGene (NASDAQ:ENGN) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

In the previous week, enGene had 7 more articles in the media than Kamada. MarketBeat recorded 8 mentions for enGene and 1 mentions for Kamada. Kamada's average media sentiment score of 1.89 beat enGene's score of 0.48 indicating that Kamada is being referred to more favorably in the news media.

Company	Overall Sentiment
enGene	Neutral
Kamada	Very Positive

64.2% of enGene shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 10.5% of enGene shares are held by insiders. Comparatively, 36.1% of Kamada shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

enGene has a beta of -0.28, meaning that its share price is 128% less volatile than the broader market. Comparatively, Kamada has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

Kamada has a net margin of 11.60% compared to enGene's net margin of 0.00%. Kamada's return on equity of 8.37% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
Kamada	11.60%	8.37%	5.85%

Kamada has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.17	N/A
Kamada	$180.46M	2.64	$20.20M	$0.38	21.82

enGene presently has a consensus target price of $11.05, indicating a potential upside of 505.23%. Kamada has a consensus target price of $13.00, indicating a potential upside of 56.82%. Given enGene's higher probable upside, equities analysts clearly believe enGene is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Kamada beats enGene on 11 of the 15 factors compared between the two stocks.

Get enGene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENGN vs. The Competition

Export

Metric	enGene	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$122.26M	$3.94B	$7.18B	$12.89B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	-0.84	11.68	273.17	25.45
Price / Sales	N/A	1,408.89	638.21	103.75
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	0.70	16.92	11.08	6.36
Net Income	-$117.30M	-$22.74M	$3.48B	$349.79M
7 Day Performance	0.83%	-0.13%	0.38%	-0.40%
1 Month Performance	1.96%	11.45%	7.89%	4.24%
1 Year Performance	-60.50%	55.66%	24.71%	15.13%

enGene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENGN enGene	3.5938 of 5 stars	$1.83 flat	$11.05 +505.2%	-60.5%	$122.26M	N/A	N/A	31	Gap Up
PRTA Prothena	2.8895 of 5 stars	$9.32 +2.5%	$24.57 +163.6%	+13.8%	$487.93M	$54.53M	N/A	130	Positive News
EVMN Evommune	2.9236 of 5 stars	$13.29 -1.4%	$41.56 +212.7%	N/A	$482.29M	$13M	N/A	45
CCCC C4 Therapeutics	1.6721 of 5 stars	$3.90 -4.9%	$7.75 +98.7%	+48.1%	$479.82M	$35.95M	N/A	150	Positive News
AGMB AgomAb Therapeutics	3.6091 of 5 stars	$13.20 -4.6%	$37.50 +184.1%	N/A	$478.33M	N/A	N/A	62	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENGN) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

enGene (ENGN) Competitors